These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 16947038)

  • 1. [DVO guideline 2006. What changes have there been in the diagnosis, prevention and treatment of osteoporosis?].
    Fassbender WJ; Stumpf UC
    Z Rheumatol; 2006 Sep; 65(5):364-6, 368-9. PubMed ID: 16947038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strontium ranelate: vertebral and non-vertebral fracture risk reduction.
    Seeman E
    Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S17-20. PubMed ID: 16735841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.
    Meunier PJ; Roux C; Seeman E; Ortolani S; Badurski JE; Spector TD; Cannata J; Balogh A; Lemmel EM; Pors-Nielsen S; Rizzoli R; Genant HK; Reginster JY
    N Engl J Med; 2004 Jan; 350(5):459-68. PubMed ID: 14749454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strontium ranelate decreases the incidence of new caudal vertebral fractures in a growing mouse model with spontaneous fractures by improving bone microarchitecture.
    Geoffroy V; Chappard D; Marty C; Libouban H; Ostertag A; Lalande A; de Vernejoul MC
    Osteoporos Int; 2011 Jan; 22(1):289-97. PubMed ID: 20204596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strontium ranelate and risk of vertebral fractures in frail osteoporotic women.
    Rolland Y; Abellan Van Kan G; Gillette-Guyonnet S; Roux C; Boonen S; Vellas B
    Bone; 2011 Feb; 48(2):332-8. PubMed ID: 20817053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antiosteoporosis medication: useful monitoring, and how long should such treatment be continued?].
    Demary W
    Z Rheumatol; 2006 Sep; 65(5):370-1, 373-7. PubMed ID: 16932950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anabolic skeletal therapy for osteoporosis.
    Girotra M; Rubin MR; Bilezikian JP
    Arq Bras Endocrinol Metabol; 2006 Aug; 50(4):745-54. PubMed ID: 17117299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapy of osteoporosis: bisphosphonates, SERM's, teriparatide and strontium].
    Uebelhart D; Frey D; Frey-Rindova P; Goerres G; Michel BA
    Z Rheumatol; 2003 Dec; 62(6):512-7. PubMed ID: 14685711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Osteoporosis priority: Reduce the number of fractures].
    Roux C
    Presse Med; 2006 Oct; 35(10 Pt 2):1527-8. PubMed ID: 17028516
    [No Abstract]   [Full Text] [Related]  

  • 10. [Anabolic treatment for osteoporosis: PTH treatment].
    Kaji H; Sugimoto T
    Clin Calcium; 2006 Sep; 16(9):1480-85. PubMed ID: 16951472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide.
    Anastasilakis AD; Polyzos SA; Avramidis A; Papatheodorou A; Terpos E
    Horm Metab Res; 2009 Jul; 41(7):559-62. PubMed ID: 19204890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men.
    Kaufman JM; Audran M; Bianchi G; Braga V; Diaz-Curiel M; Francis RM; Goemaere S; Josse R; Palacios S; Ringe JD; Felsenberg D; Boonen S
    J Clin Endocrinol Metab; 2013 Feb; 98(2):592-601. PubMed ID: 23341486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Advances in the field of osteoporosis].
    Vignot E; Delmas PD
    Rev Prat; 2007 Oct; 57(15):1629-31. PubMed ID: 18080418
    [No Abstract]   [Full Text] [Related]  

  • 14. Mixed-treatment comparison of anabolic (teriparatide and PTH 1-84) therapies in women with severe osteoporosis.
    Migliore A; Broccoli S; Massafra U; Bizzi E; Frediani B
    Curr Med Res Opin; 2012 Mar; 28(3):467-73. PubMed ID: 22256908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide.
    Carvalho NN; Voss LA; Almeida MO; Salgado CL; Bandeira F
    J Clin Endocrinol Metab; 2011 Sep; 96(9):2675-80. PubMed ID: 21752890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
    Sugimoto T; Shiraki M; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Kuroda T; Nakamura T
    Curr Med Res Opin; 2013 Mar; 29(3):195-203. PubMed ID: 23259702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The efficacy of strontium ranelate (Osseor) on fractures in osteoporosis].
    Novak S
    Reumatizam; 2008; 55(2):75-7. PubMed ID: 19024282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone-forming agents in the management of osteoporosis.
    Neuprez A; Reginster JY
    Best Pract Res Clin Endocrinol Metab; 2008 Oct; 22(5):869-83. PubMed ID: 19028361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Update on the DVO Guideline 2023 "Prophylaxis, diagnosis and treatment of osteoporosis in postmenopausal women and in men aged over 50"-What's new for rheumatology?].
    Pfeil A; Lange U
    Z Rheumatol; 2024 Jun; 83(5):401-406. PubMed ID: 38512355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
    Reginster JY; Felsenberg D; Boonen S; Diez-Perez A; Rizzoli R; Brandi ML; Spector TD; Brixen K; Goemaere S; Cormier C; Balogh A; Delmas PD; Meunier PJ
    Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.